Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

19.65 UNCHANGED
Streaming Delayed Price Updated: 3:16 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 388,215
Open 19.90
Bid (Size) 19.64 (1)
Ask (Size) 19.67 (1)
Prev. Close 19.65
Today's Range 19.27 - 20.18
52wk Range 14.59 - 35.84
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here are the top movers in Tuesday's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga

Performance

YTD
-29.9%
-29.9%
1 Month
-0.6%
-0.6%
3 Month
+14.2%
+14.2%
6 Month
-29.4%
-29.4%
1 Year
-26.7%
-26.7%

More News

Read More
Tuesday's session: top gainers and losers
Via Chartmill
Earnings Scheduled For August 4, 2025
Via Benzinga
Sterling Infrastructure Posts Better-Than-Expected Earnings, Joins Lemonade, DigitalOcean Holdings, Lattice Semiconductor And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Traders are paying attention to the gapping stocks in Tuesday's session.
Via Chartmill
These stocks are moving in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Castle (CSTL) Q2 Revenue Tops Estimates
Via The Motley Fool
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Castle Biosciences Inc (NASDAQ:CSTL) Surges After Posting Strong Q2 2025 Earnings Beat
Via Chartmill
Topics Earnings
Castle Biosciences Reports Second Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Examining the Future: Castle Biosciences's Earnings Outlook
Via Benzinga
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
From Castle Biosciences, Inc.
Via GlobeNewswire
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
From Castle Biosciences, Inc.
Via GlobeNewswire
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
From Castle Biosciences, Inc.
Via GlobeNewswire
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
From Castle Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Castle Biosciences, Inc. - Common stock publicly traded?
Yes, Castle Biosciences, Inc. - Common stock is publicly traded.
What exchange does Castle Biosciences, Inc. - Common stock trade on?
Castle Biosciences, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Castle Biosciences, Inc. - Common stock?
The ticker symbol for Castle Biosciences, Inc. - Common stock is CSTL on the Nasdaq Stock Market
What is the current price of Castle Biosciences, Inc. - Common stock?
The current price of Castle Biosciences, Inc. - Common stock is 19.65
When was Castle Biosciences, Inc. - Common stock last traded?
The last trade of Castle Biosciences, Inc. - Common stock was at 08/08/25 03:16 PM ET
What is the market capitalization of Castle Biosciences, Inc. - Common stock?
The market capitalization of Castle Biosciences, Inc. - Common stock is 494.54M
How many shares of Castle Biosciences, Inc. - Common stock are outstanding?
Castle Biosciences, Inc. - Common stock has 495M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.